Cargando…

Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany

AIMS: Treatment of iron deficiency (ID) in patients with heart failure (HF) with intravenous iron substitution [ferric carboxymaltose (FCM)] has previously shown significant improvements in exercise capacity, New York Heart Association (NYHA) functional class, quality of life, and reduction of hospi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Theidel, Ulrike, Väätäinen, Saku, Martikainen, Janne, Soini, Erkki, Hardt, Thomas, Doehner, Wolfram
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542731/ https://www.ncbi.nlm.nih.gov/pubmed/28772041 http://dx.doi.org/10.1002/ehf2.12179

Ejemplares similares

Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia
por: Friedrisch, João Ricardo, et al.
Publicado: (2015)

Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy
por: Froessler, Bernd, et al.
Publicado: (2018)

Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France
por: Bourguignon, Sandrine, et al.
Publicado: (2019)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anaemia – reply
por: Cancado, Rodolfo Delfini, et al.
Publicado: (2020)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia: Letter to Editor
por: Kanshaiym, Sakiyeva, et al.
Publicado: (2020)

Intravenous ferric carboxymaltose for the management of iron deficiency and iron deficiency anaemia in children and adolescents: a review
por: Aksan, Aysegül, et al.
Publicado: (2022)

Safety, pharmacokinetics, and pharmacodynamics of intravenous ferric carboxymaltose in children with iron deficiency anemia
por: Korczowski, Bartosz, et al.
Publicado: (2023)

Ferric carboxymaltose for the treatment of iron‐deficient heart failure patients: a systematic review and meta‐analysis
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Intravenous ferric carboxymaltose and ferric derisomaltose alter the intestinal microbiome in female iron-deficient anemic mice
por: Rieg, Timo, et al.
Publicado: (2023)

Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia
por: Seid, Melvin H., et al.
Publicado: (2017)

Assessing the costs and benefits of perioperative iron deficiency anemia management with ferric carboxymaltose in Germany
por: Froessler, Bernd, et al.
Publicado: (2018)

Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF) and Iron Deficiency in Switzerland
por: Brock, Elisabeth, et al.
Publicado: (2022)

Efficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia
por: Basha, Ahmad, et al.
Publicado: (2021)

Treatment of Iron Deficiency With Intravenous Ferric Carboxymaltose in General Practice: A Retrospective Database Study
por: Kuster, Martina, et al.
Publicado: (2015)

MON-338 Severe Hypophosphatemia Induced by Intravenous Ferric Carboxymaltose Therapy for Iron Deficiency Anemia
por: Tam, Matthew, et al.
Publicado: (2020)

Cost-Minimization Analysis Favours Intravenous Ferric Carboxymaltose over Ferric Sucrose for the Ambulatory Treatment of Severe Iron Deficiency
por: Calvet, Xavier, et al.
Publicado: (2012)

Ferric carboxymaltose for treatment of iron deficiency and iron deficiency anemia caused by abnormal uterine bleeding
por: Hagras, Ahmed M., et al.
Publicado: (2022)

Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency(†)
por: Ponikowski, Piotr, et al.
Publicado: (2015)

Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—a systematic review and meta‐analysis
por: Schaefer, Benedikt, et al.
Publicado: (2020)

Efficacy of ferric carboxymaltose in iron deficiency anemia patients scheduled for pancreaticoduodenectomy
por: Park, Jangho, et al.
Publicado: (2023)

High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment
por: Boots, Johannes M. M., et al.
Publicado: (2022)

Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial
por: Adkinson, N. Franklin, et al.
Publicado: (2018)

Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol
por: Schindler, Christoph, et al.
Publicado: (2017)

Ferric Carboxymaltose in the Treatment of Iron-Deficiency Anaemia in Paediatric Patients with Anastomotic Ulcers
por: Udina, Chiara, et al.
Publicado: (2022)

Evaluation of Minimal Optimal Dose of Intravenous Ferric Carboxymaltose for Treatment of Iron Deficiency Anemia and Risk of Transient Hyperferritinemia
por: Alharbi, Ahmad A, et al.
Publicado: (2022)

Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency Anemia
por: Hussain, Iftikhar, et al.
Publicado: (2013)

Intravenous ferric carboxymaltose for anaemia in pregnancy
por: Froessler, Bernd, et al.
Publicado: (2014)

The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study
por: Jankowska, Ewa A, et al.
Publicado: (2011)

FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia
por: Macdougall, Iain C., et al.
Publicado: (2014)

Safety and Efficacy of Intravenous Ferric Carboxymaltose (750 mg) in the Treatment of Iron Deficiency Anemia: Two Randomized, Controlled Trials
por: Barish, Charles F., et al.
Publicado: (2012)

Ferric Carboxymaltose-Mediated Attenuation of Doxorubicin-Induced Cardiotoxicity in an Iron Deficiency Rat Model
por: Toblli, Jorge Eduardo, et al.
Publicado: (2014)

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency
por: van Veldhuisen, Dirk J., et al.
Publicado: (2017)

Iron Deficiency Anemia with Menorrhagia: Ferric Carboxymaltose a Safer Alternative to Blood Transfusion
por: Mishra, Vineet, et al.
Publicado: (2018)

Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy
por: Rognoni, Carla, et al.
Publicado: (2019)

Comparison of ferric Carboxymaltose and iron sucrose complex for treatment of iron deficiency anemia in pregnancy- randomised controlled trial
por: Jose, Ambily, et al.
Publicado: (2019)

Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron
por: Lichtenstein, Gary R., et al.
Publicado: (2018)

Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for iron deficiency anemia in obstetric and gynecologic patients: A systematic review and meta-analysis
por: Shin, Hye Won, et al.
Publicado: (2021)

Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial
por: Filippatos, Gerasimos, et al.
Publicado: (2013)

Efficacy and Safety of Intravenous Ferric Carboxymaltose Treatment of Iron Deficiency Anaemia in Patients with Corpus Atrophic Gastritis: A Retrospective Study
por: Dottori, Ludovica, et al.
Publicado: (2023)

Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials
por: Naqash, Amreen, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o5i975morsmfr29746pq3349ia